In early 2026, BioPharmaChem Ireland published its Sustainability and Responsible Care Report — and the headline figure inside it stopped even seasoned industry observers. Irish pharmaceutical exports grew 29% in 2024, reaching €99.9 billion. The sector that began with Pfizer setting up a small molecule facility in Ringaskiddy in the 1960s now generates more export revenue than any other sector in the Irish economy, accounting for a substantial share of Ireland's total goods exports of approximately €230 billion. To put the number in perspective: Irish biopharma exports in 2024 were worth roughly €20,000 for every man, woman and child on the island of Ireland.
But it is the second number in that report that deserves equal attention, because it answers a question that has been put to the Irish pharma industry with increasing urgency in recent years: can a sector this size actually reduce its environmental footprint while continuing to grow? The answer, based on 2024 data verified by BioPharmaChem Ireland across its approximately 80 member companies, is yes. Electricity-related carbon dioxide emissions across the Irish biopharma sector fell by 30.5% over the measured period, even as exports surged. That decoupling — more output, fewer emissions — is the data point that will define the Irish biopharma sector's relationship with sustainability regulation and investor ESG expectations for years to come.
How Ireland Became the World's Third-Largest Pharmaceutical Exporter
Ireland's journey from an agricultural economy to a global pharmaceutical manufacturing hub is one of the more remarkable industrial transformations in modern European economic history. The foundation was laid in the early 1960s, when the Irish government made a deliberate strategic decision to attract foreign direct investment through competitive corporate tax rates and a focus on manufacturing exports. Pfizer in Ringaskiddy and Merck in Ballydine were among the earliest arrivals in the 1960s and 1970s, establishing the small molecule cluster that formed the bedrock of the Irish pharma industry for its first three decades.
The transition from small molecule to biologics manufacturing over the past 25 years transformed the sector's scale and sophistication. Ireland now operates 25 large-scale biologics facilities, complementing the existing small molecule cluster, with the sector employing over 50,000 people directly and supporting a much larger ecosystem of professional services, engineering, logistics and energy companies. According to IDA Ireland data, more than €15 billion in biopharma FDI has been attracted to Ireland in the last decade alone. Nineteen of the world's top 20 pharmaceutical companies maintain a presence in Ireland. The country's regulatory track record — a consistently high performance in inspections by the US Food and Drug Administration and the European Medicines Agency — has been central to that investment case, as has the quality of STEM talent produced by Irish universities, with Ireland recording the highest rate of STEM graduates per capita in the EU27 as of 2022 at 40.1 per 1,000 people aged 20 to 29.
The Sustainability Story: Exports Up, Emissions Down
The BioPharmaChem Ireland Responsible Care Report, published in early 2026, is the most detailed public accounting of the Irish biopharma sector's environmental performance to date. The 30.5% reduction in electricity-related CO₂ emissions has been driven primarily by corporate power purchase agreements through which major manufacturers have contracted directly with Irish renewable energy generators, securing clean electricity at competitive long-term prices while removing the need to rely on fossil-fuel-generated grid electricity. This approach has proven more financially efficient than many companies initially modelled, and the renewable electricity purchasing pathway has now been adopted as standard practice across the majority of larger BPCI member companies.
The report also establishes what BPCI describes as a new baseline for sustainable biopharma manufacturing — one that explicitly acknowledges the remaining challenges alongside the progress. Hazardous waste generation has widened as a concern, driven by growth in complex active pharmaceutical ingredient production. The manufacturing of biologics and advanced therapy medicinal products produces hazardous waste streams that require specialist treatment, and as the number and complexity of products manufactured in Ireland has grown, so has the volume of hazardous waste generated. BPCI is direct about this gap: the report acknowledges it and sets the 2031 cycle as the test of whether commitments made now translate into measurable improvement.
The National Life Sciences Strategy: Coming Before Ireland Takes the EU Presidency
The strength of the sector's performance in 2024 and 2025 coincides with a significant policy moment. Ireland is preparing to publish its first National Life Sciences Strategy — a commitment made in the Programme for Government 2025 and confirmed in a consultation process launched by the Department of Enterprise, Tourism and Employment in October 2025. The strategy is expected to be published before the end of June 2026, timed deliberately to coincide with Ireland taking up the EU Council Presidency in July. That timing is strategic: with life sciences now sitting more prominently on the EU's policy agenda through initiatives including the proposed Critical Medicines Act, the planned European Innovation Act and proposed reforms to pharmaceutical legislation, Ireland wants to shape the European conversation about life sciences competitiveness from the position of holding the Presidency.
The strategy's scope covers not just manufacturing but research and innovation, patient access, talent and skills, sustainability, and digital health — a recognition that Ireland's competitive advantage in life sciences cannot rest indefinitely on manufacturing alone and must extend into R&D, advanced therapy development and the data and AI-enabled manufacturing of the next generation. Ireland is already classified as a "Strong Innovator" in the 2025 European Innovation Scoreboard, with particular strengths in immunology, genetics and analytics that align with where the global biopharma industry is heading.
What It Means for Ireland in 2026 and Beyond
The biopharma sector's 2024 performance — €99.9 billion in exports, 30% fewer electricity emissions — demonstrates that the investment case for Ireland remains strong despite increasing global competition from incentive programmes in the United States, France and Germany. IDA Ireland's Rory Mullen has been explicit that Ireland's pitch to incoming investors is no longer just about tax competitiveness but about the depth of the ecosystem: the talent, the regulatory track record, the research infrastructure at NIBRT, SSPC, PMTC and Digital Manufacturing Ireland, and the geographic clustering of companies that enables supply chain resilience at continental scale. That ecosystem case is, arguably, more durable than a tax incentive that competitor jurisdictions can match.
The sector is also forecast to continue growing in employment terms: Ireland's biopharma industry is projected to add 21,000 jobs by 2027, with significant hiring activity through 2026, concentrated in digital, automation and data roles alongside the traditional manufacturing, quality and regulatory functions. The skills that will be most in demand are precisely those that bridge the gap between the biological and the digital: professionals who understand both GMP manufacturing and AI-driven process optimisation, both regulatory science and data analytics. Irish universities and institutions like NIBRT, which now delivers more than 250,000 training days annually across Level 6 to Level 10 qualifications, are the infrastructure through which that talent pipeline is being built.
The Bottom Line
Irish biopharma exports reached €99.9 billion in 2024 while the sector cut its electricity-related carbon emissions by 30.5%. That combination — growth and decarbonisation simultaneously — is the data-backed case Ireland will be making to investors, regulators and policymakers as it takes up the EU Council Presidency in July 2026 and publishes its first National Life Sciences Strategy. The numbers make the argument better than any pitch document.